NCT06587022 Delineation of Target Volume of Stereotactic Radiotherapy for Spinal Tumors
| NCT ID | NCT06587022 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University Third Hospital |
| Condition | Spinal Tumor |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2017-01-01 |
| Primary Completion | 2026-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2017-01-01 with a primary completion date of 2026-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study was to compare efficacy and side effects of two target delineation methods for stereotactic radiotherapy of metastatic spinal tumors.
Eligibility Criteria
Inclusion Criteria: * Patients with spinal metastases or primary tumors receiving stereotactic radiotherapy; * Patients with sufficent pre-treatment imaging data * Patients who can cooperate with imaging review and follow-up after radiotherapy. Exclusion Criteria: * Patients with an expected survival of less than 3 months; * Patients with second-course radiotherapy; * Patients with physical conditions that cannot tolerate stereotactic radiotherapy; * Patients with extensive spinal metastasis and no local therapeutic value
Contact & Investigator
Hongqing Zhuang
STUDY DIRECTOR
Peking University Third Hospital
Frequently Asked Questions
Who can join the NCT06587022 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Spinal Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06587022 currently recruiting?
Yes, NCT06587022 is actively recruiting participants. Contact the research team at hongqingzhuang@163.com for enrollment information.
Where is the NCT06587022 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06587022 clinical trial?
NCT06587022 is sponsored by Peking University Third Hospital. The principal investigator is Hongqing Zhuang at Peking University Third Hospital. The trial plans to enroll 500 participants.